Advertisement

Pfizer may shed OTC business

NEW YORK, Feb. 8 (UPI) -- Pfizer said this week it is mulling a possible spinoff of its over-the-counter business.

Pfizer's OTC arm, which could reportedly fetch $10 billion to $12 billion on the open market, includes such top-selling drugstore products as Listerine mouthwash, Rogaine treatment for hair loss and Visine eye drops.

Advertisement

The drug giant said it would hold an analyst meeting Friday to discuss details of the potential move. The company was mum as to potential buyers of its OTC division.

Latest Headlines